RNAC — Cartesian Therapeutics Balance Sheet
0.000.00%
- $480.67m
- $377.25m
- $26.00m
Annual balance sheet for Cartesian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 89.9 | 139 | 128 | 135 | 76.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5 | 7.22 | 9.91 | 9.76 | 8.85 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 96.7 | 151 | 144 | 148 | 90.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.52 | 12.3 | 12 | 14.4 | 12.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 99.6 | 165 | 160 | 166 | 305 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 34.9 | 81.5 | 72.3 | 25.1 | 68.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 91.2 | 183 | 137 | 72.1 | 445 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 8.4 | -18 | 22.5 | 93.8 | -140 |
Total Liabilities & Shareholders' Equity | 99.6 | 165 | 160 | 166 | 305 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |